Electromed, Inc. Form 10-Q Summary
Reporting period: Three months ended September 30, 2013, the first quarter of fiscal 2014. Results are unaudited and should be read with the fiscal 2013 Form 10-K.
Business context
Electromed develops, manufactures, and markets airway-clearance products using High Frequency Chest Wall Oscillation therapy, including the SmartVest Airway Clearance System. Products are sold to home-care, government, institutional, and international markets.
Financial performance and liquidity
| Metric | Q1 FY2014 | Q1 FY2013 | Change |
|---|---|---|---|
| Net revenue | $3.418 million | $4.031 million | Down 15.2% |
| Gross profit | $2.356 million | $2.821 million | Down 16.5% |
| Gross margin | 68.9% | 70.0% | Down 1.1 percentage points |
| Operating loss | $577,203 | $96,370 | Loss increased |
| Net loss | $335,405 | $71,108 | Loss increased |
| Loss per share | $0.04 | $0.01 | Loss increased |
| Cash provided by operations | $741,983 | $114,014 | Increased |
| Capital expenditures | $148,915 | $197,020 | Decreased |
Approximate operating and net margins were negative 16.9% and negative 9.8%, respectively, compared with negative 2.4% and negative 1.8% in the prior-year quarter. The effective tax rate was 43.4%, producing a $257,000 income tax benefit.
Cash and cash equivalents were $1.077 million at September 30, 2013, compared with $503,564 at June 30, 2013. Working capital was approximately $10 million. Accounts receivable declined to $7.989 million from $9.014 million at June 30, supporting operating cash flow.
Total debt was approximately $1.371 million, consisting primarily of $1.318 million of long-term Term Loan A and $52,662 of current maturities. The company had no borrowings on its $2.25 million revolving line of credit and reported $2.25 million of net unused availability, subject to borrowing-base limitations.
Material changes versus the prior comparable period
- Home-care revenue declined 20.5% to approximately $2.843 million because of lower average selling prices, pricing pressure, fewer referrals, and longer third-party payer approval processes.
- International revenue increased 36.7% to approximately $149,000.
- Government and institutional revenue increased 22.4% to approximately $426,000, including a $127,000 increase in government sales.
- Gross margin declined because lower sales reduced manufacturing-cost leverage and the referral mix included lower-reimbursement cases.
- SG&A decreased 3.3% to approximately $2.724 million, although payroll and professional fees increased. Legal and professional fees were affected by shareholder-related litigation.
- Research and development expense increased 107% to approximately $209,000, or 6.1% of revenue.
- Interest expense decreased 43.9% to approximately $23,000 because of lower average debt outstanding.
- Operating cash flow improved primarily because accounts receivable collections generated approximately $1.025 million of cash, compared with $435,000 in the prior-year quarter.
Outlook, risks, contingencies, and unusual items
- Management stated that increased revenue is necessary to return to profitability and expects long-term gross margins to return to historical levels above 70% if sales grow.
- Third-party payer reimbursement remains a significant risk. Pricing pressure, added claims procedures, and the decentralized contracting process of a major payer have delayed approvals and required additional administrative effort.
- The revolving credit line expires December 31, 2013 unless renewed. Management expected renewal or alternative financing but stated that financing on favorable terms, or at all, cannot be assured.
- The credit facility requires minimum liquidity, minimum EBITDA, fixed-charge and leverage ratios, and other covenants. Noncompliance could result in acceleration of debt, loss of borrowing access, or foreclosure on substantially all company assets.
- The company settled litigation with its former chief executive officer for a $150,000 payment and entered into a separate settlement with a shareholder-proposal proponent. The company is seeking insurance coverage for related professional fees, but coverage is not guaranteed.
- The company maintains a $680,000 warranty reserve and provides lifetime warranties for prescribed U.S. patients and three-year warranties for institutional and non-U.S. sales.
- Management reported effective disclosure controls and no material changes to internal control over financial reporting.
Investor verification checklist
- Verify renewal or replacement of the $2.25 million revolving credit facility before its December 31, 2013 expiration.
- Monitor compliance with minimum liquidity, EBITDA, fixed-charge, and leverage covenants.
- Assess whether home-care referrals, reimbursement rates, payer contracting, and approval times improve.
- Review the sustainability of operating cash flow, particularly the extent to which it depends on reductions in accounts receivable.
- Confirm the amount of litigation-related costs ultimately reimbursed by insurance.
- Evaluate whether revenue growth restores gross margins above 70% and supports a return to profitability.